← FDA Drug Approvals (Drugs@FDA)

TRIJARDY XR

NDA · New Drug Application · Sponsor: BOEHRINGER INGELHEIM · Approved 2020-01-27

Drug application

FDA Application #

NDA212614

Application type

New Drug Application

Brand name

TRIJARDY XR

Generic name

EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE

Active ingredients

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Dosage form

TABLET, EXTENDED RELEASE

Route

ORAL

Marketing status

Prescription

Sponsor

BOEHRINGER INGELHEIM

Manufacturer

Boehringer Ingelheim Pharmaceuticals, Inc.

First approval

2020-01-27

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown